• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Best Read Articles on Formularies and Formulary Changes in 2021

News
Article

Our best read stories about formularies include news about 2022 formularies from CVS Caremark and Express Scripts.

Express Scripts Releases List of 2022 Formulary Exclusions

Four products on the preferred list this year will be excluded next year.

Read more

Non-opioid Pain Therapeutic Achieves More Than 100 Formulary Approvals

The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.

Read more

CVS Caremark Announces Formulary for 2022

CVS Caremark has removed 10 branded products from its formulary and added about 30 additional products.

Read more

Cigna Releases Formulary Changes for 2022

Cigna plans to remove 45 drugs from its Standard Prescription Drug List and add restrictions for other therapeutics.

Read more

Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary

Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.

Read more

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.